SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia
Green certification is the top tier of the globally recognized My Green Lab program for laboratory sustainability excellence
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity.
The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development.
My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green certification is the program’s highest designation, reserved for laboratories that demonstrate exceptional, independently verified performance in reducing environmental impact while maintaining scientific excellence. Gold certification represents advanced performance and a clear progression toward Green.
SK pharmteco began its journey to achieve My Green Lab certifications in the fall of 2024, with a long-term goal of reaching the highest certification level by 2030.
“Achieving Green and Gold certifications across multiple regions in parallel is not just a compliance milestone; it signals where scientific operations must go next,” said Darryl Ratty, Executive Director, Global ESG of SK pharmteco. “Sustainability in R&D and quality labs is no longer a side project; it’s a performance expectation. We’re embedding it into how science is planned, executed, and validated across our global laboratory network.”
SK pharmteco's pursuit of My Green Lab Certification directly supports its three-pronged sustainability strategy: Responsible Manufacturing through optimized lab practices, Decarbonizing Operations with enhanced energy efficiency, and Championing Waste-Less Innovation via robust waste reduction initiatives. Additionally, it demonstrates the company’s ongoing commitment to integrating sustainable practices into every facet of its operations, contributing to a greener future for the industry.
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028846076/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1888 Studios and Paramount Announce Landmark 10-Year Lease Agreement to Unlock Access to Newly Enhanced Film and Television Tax Incentives28.10.2025 21:35:00 CET | Press release
1888 Studios, a state-of-the-art, 1.6 million square foot film and television production campus in Bayonne, NJ, to be built for movie makers by movie makers, announced today that Paramount, a Skydance Corporation, (“Paramount”) (NASDAQ: PSKY), a leading, next generation global media and entertainment company, has signed a landmark minimum 10-year lease agreement. Paramount has committed to occupy more than 285,000 square feet of the facility, establishing a major production hub in New Jersey. Paramount’s commitment further cements the state as a premier destination for film and television production, backed by a leading tax incentive program. Currently under development by Togus Urban Renewal, 1888 Studios is set to become the largest campus-style production facility in the Northeast and one of the largest in the nation. The 58-acre facility will offer over 1.1 million square feet of production space spanning 23 smart sound stages with a minimum of 40-foot clear ceilings; production su
SS&C Introduces AI Agents to Simplify Financial Services and Healthcare Operations28.10.2025 21:05:00 CET | Press release
Proven, prebuilt AI agents from a leader in responsible AI governance enable first adopter, American Life & Security Corp., to streamline private credit operations SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of its AI agent catalogue for financial services and healthcare firms. The outcome-focused AI agents are designed to simplify complex operations such as credit processing and contract validation. Delivered as a managed service, the agents help organizations overcome talent shortages and operational bottlenecks securely and at-scale. One of the first customers to evaluate an SS&C AI Agent is American Life, a rapidly growing carrier in the annuity and retirement space based in Lincoln, Nebraska. The firm is leveraging and evaluating SS&C’s Credit Agreement Document Agent to streamline processing within its private credit operations. The AI agent continuously reviews and updates lengthy loan documents, cutting time and errors associated with manual revie
Logitech Announces Q2 Fiscal Year 2026 Results28.10.2025 21:05:00 CET | Press release
Operational Excellence and Strategic Priorities Drive Strong Second Quarter SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the second quarter of Fiscal Year 2026. Sales were $1.19 billion, up 6 percent in US dollars and 4 percent in constant currency compared to Q2 of the prior year. GAAP gross margin was 43.4 percent, down 20 basis points compared to Q2 of the prior year. Non-GAAP gross margin was 43.8 percent, down 30 basis points compared to Q2 of the prior year. GAAP operating income was $191 million, up 19 percent compared to Q2 of the prior year. Non-GAAP operating income was $230 million, up 19 percent compared to Q2 of the prior year. GAAP earnings per share (EPS) was $1.15, up 21 percent compared to Q2 of the prior year. Non-GAAP EPS was $1.45, up 21 percent compared to Q2 of the prior year. Cash flow from operations was $229 million. The quarter-ending cash balance was $1.
IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction28.10.2025 21:04:00 CET | Press release
Collaboration underscores commitment in scaling one of the key challenges to useful quantum computing applications IQM Quantum Computers, a global leader in superconducting quantum computers, today announced it will integrate NVIDIA’s NVQLink into its quantum computers to scale error correction, a key component for realising quantum computing applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028095798/en/ IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction NVQLink is an open and interoperable platform integrated with NVIDIA CUDA-Q that connects quantum hardware to AI supercomputing. It provides low-latency and high-throughput connectivity between quantum computers and Graphics Processing Unit (GPU)-accelerated compute, enabling the real-time orchestration of computational tasks needed for running useful hybrid quantum-classical applications and quantum error correction. While tod
Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics28.10.2025 17:34:00 CET | Press release
Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual, transferrable, sublicensable, freedom-to-operate, license for USA, Europe, Latam, Africa and Central Asia with option to expand rights into Asia-Pacific in 2026, covering patents and other intellectual property necessary for development, manufacturing, and sales of the next-generation CoolMPS sequencing platform that will provide faster, cheaper and more accurate whole genome sequencing and other omics tests. The agreement includes payments linked to technology transfer and revenue-based royalties. Swiss Rockets’ future development will focus on advancing CoolMPS products with innovative read barcoding. These innovations will support comprehensive omics testing for advanced genomic research and molecular health monitoring. CoolMPS chemistry provides the most advanced MPS/NGS generating cos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom